Abstract: Three novel variants of the SLC25A13 gene were identified for the first time, providing a reliable molecular reference and expanding the SLC25A13 gene spectrum in patients with CD. Plasma bile acid profiles could be a potential biomarker for non-invasive early diagnosis of patients with intrahepatic cholestasis caused by CD.
Introduction
Citrin deficiency (CD) is an autosomal recessive metabolic disorder caused by mutations in the SLC25A13 gene, which encodes the mitochondrial aspartate-glutamate carrier. In infants, this condition often manifests as Neonatal Intrahepatic Cholestasis (NICCD). Clinical presentation typically includes jaundice, significantly elevated alpha-fetoprotein (AFP), and hypoglycemia. However, these symptoms overlap considerably with other liver diseases, such as idiopathic cholestasis (IC), making early and accurate diagnosis challenging. While genetic testing remains the gold standard, the known mutation spectrum of SLC25A13 is incomplete. This study aims to expand the genetic landscape of CD and identify specific biochemical markers to aid in non-invasive diagnosis.
Methods
The researchers conducted a retrospective analysis of 14 patients diagnosed with CD and 30 age-matched controls with idiopathic cholestasis (IC). Genetic analysis was performed using Next-Generation Sequencing (NGS) followed by Sanger sequencing for pedigree validation. Additionally, plasma bile acid profiling was conducted using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) to quantify 15 different bile acid species, providing a high-resolution metabolic snapshot of the patients.
Results
Genetic Analysis and Novel Variants
The study identified eight different SLC25A13 mutations across the patient cohort. Notably, three novel variants were discovered and validated: c.1043C>T (p.P348L), c.1216dupG (p.A406 Gfs*13), and c.135G>C (p.L45F). These findings significantly expand the known genetic spectrum of citrin deficiency, particularly within East Asian populations where the condition is more prevalent.
Biochemical Markers and Bile Acid Profiling
Clinical data revealed that 92% of CD patients had massively elevated AFP levels (>3,000 ng/mL), and 85% exhibited an AST/ALT ratio greater than 1, a useful clinical indicator of mitochondrial dysfunction.
The most significant finding was the identification of a specific "bile acid signature" that distinguishes CD from IC. Quantitative analysis showed that three specific conjugated primary bile acids were significantly elevated (p < 0.01) in the CD group compared to the IC group: Glycochenodeoxycholic acid (GCDCA), Taurocholate (TCA), and Taurochenodeoxycholic acid (TCDCA).
Conclusion
This study provides new molecular references for the diagnosis of citrin deficiency by identifying three novel SLC25A13 variants. Furthermore, the discovery of a distinct plasma bile acid profile—specifically the elevation of GCDCA, TCA, and TCDCA—offers a potential non-invasive biomarker for early diagnosis. These findings facilitate quicker clinical decision-making, allowing for early dietary intervention (such as lactose-free, MCT-enriched formulas) which is crucial for preventing progression to more severe liver complications.
Summary updated